“When does Yes mean No”

David Healy May 28, 2013
How informed consent became a cover for the companies.
http://davidhealy.org/when-does-yes-mean-no/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DrDavidHealy+%28Dr.+David+Healy%29

NAMI stakeholders advisory group:
http://www.nami.org/Template.cfm?Section=ACT-TA_Center&template=/ContentManagement/ContentDisplay.cfm&ContentID=51807

With highly valued research subject-the longitudal studies-what line seperates “thereputic leisioning ” and “mutilation”?
How do you classify such things-secondary benefince or social justice?
When the objective science breaks down could we turn toward an objective system that places a research subject in with a voice?

“While there is no ‘one size fits all’ route for JLA priority setting, the following are integral features of all JLA Priority Setting Partnerships:

* the principle of patients, carers and clinicians working together
* methodological transparency
* the declaration of interests
* working with the UK Database of Uncertainties about the Effects of Treatments (UK DUETs)”
http://www.jlaguidebook.org/jla-guidebook.asp?val=5

You see the answer to Beecher’s question could be multiple choice and the burden of research could have been shouldered by all involved-not by just the patients.

Or patients creating more patients for the sole purpose of material gain.

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s